Innate Pharma Valuation Multiples

Innate Pharma Overview

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Founded

1999

HQ

Employees

181

Website

innate-pharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $18M

EBITDA: $13M

EV

$138M

Valuation Multiples

Multiples.vc

Start free trial

Innate Pharma Financials

Innate Pharma reported last 12-month revenue of $18M and EBITDA of $13M.

In the same LTM period, Innate Pharma generated $13M in EBITDA and had net loss of ($50M).

Innate Pharma P&L

In the most recent fiscal year, Innate Pharma reported revenue of $10M and EBITDA of ($33M).

Innate Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Innate Pharma Stock Performance

Innate Pharma has current market cap of $152M, and enterprise value of $138M.

Innate Pharma's stock price is $1.62.

Innate Pharma Valuation Multiples

Innate Pharma trades at 7.6x EV/Revenue multiple, and 11.0x EV/EBITDA.

Innate Pharma Financial Valuation Multiples

As of April 19, 2026, Innate Pharma has market cap of $152M and EV of $138M.

Equity research analysts estimate Innate Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Innate Pharma has a P/E ratio of (3.0x).

Innate Pharma Margins & Growth Rates

Innate Pharma's revenue in the last 12 month grew by 166%.

Innate Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.

Innate Pharma's rule of 40 is 1345% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Innate Pharma's rule of X is 2877% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Innate Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Innate Pharma M&A Activity

Innate Pharma acquired XXX companies to date.

Last acquisition by Innate Pharma was on XXXXXXXX, XXXXX. Innate Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Innate Pharma Investment Activity

Innate Pharma invested in XXX companies to date.

Innate Pharma made its latest investment on XXXXXXXX, XXXXX. Innate Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).